Skip to main
ACXP

ACXP Stock Forecast & Price Target

ACXP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Acurx Pharmaceuticals has received positive feedback from both the FDA and EMA, positioning its antibiotic candidate, ibezapolstat (IBZ), favorably ahead of its Phase 3 trial in adult populations, which may enhance investor confidence. Additionally, IBZ has demonstrated encouraging antimicrobial activity and a favorable safety profile, underscoring its potential for addressing critical infections in a clinical setting. The recent endorsement from the Pediatric Committee of the EMA regarding the Pediatric Investigation Plan (PIP) for IBZ further highlights the company's commitment to expanding its therapeutic applications, suggesting a robust development pipeline.

Bears say

Acurx Pharmaceuticals Inc is currently facing significant valuation risks stemming from its clinical-stage status, which inherently limits revenue generation and increases dependency on funding for further development of its antibiotic candidates. The company's focus on a new class of antibiotics, while addressing urgent public health issues, may encounter market entry challenges and regulatory hurdles, which could impede financial advancement. Additionally, the lack of established commercial products leads to uncertainty regarding future profitability, making the stock's outlook more precarious.

ACXP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acurx Pharmaceuticals LLC (ACXP) Forecast

Analysts have given ACXP a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACXP has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acurx Pharmaceuticals LLC (ACXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.